PharmaTher develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting novel delivery methods to enhance patient outcomes. The Company’s lead product is KETARX™ (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The Company is commercializing PharmaPATCH (microneedle patch) and PharmaDOSE (enteric coated) with its partners to deliver psychedelics, stem cells, gene therapy, and drugs for medical countermeasures (i.e. biothreats, infectious diseases).